News
Moderna is preparing to test Health Secretary Robert F. Kennedy Jr.'s tougher vaccine policies with a combination flu-COVID ...
Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...
On Monday, Moderna published the results of a late-stage study of mRNA-1010, its seasonal flu vaccine. In a phase 3 clinical ...
Moderna this week announced positive data from a phase 3 trial of its messenger RNA vaccine against seasonal influenza, which ...
The Cambridge biotech believes packaging the two immunizations together will lead to higher uptake of COVID vaccines.
Seasonal flu-related hospitalizations and outpatient visits reached a 15-year high during the 2024-25 season, according to ...
1d
HealthDay on MSNModerna’s New Flu Shot Shows Strong Results in Older AdultsAn mRNA-based flu vaccine has the potential advantage to more precisely match circulating strains, support rapid response in a future influenza pandemic, and pave the way for COVID-19 combination ...
The virus has not yet evolved to spread efficiently between people. Excellent vaccine technology exists, but the government ...
RNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed ...
Moderna said on Monday its influenza vaccine was found to be 26.6% more effective than an approved annual flu shot from GSK ...
Moderna's flu vaccine shows positive late-stage trial results, paving way for combination Covid shot
Moderna on Monday said its experimental mRNA-based flu vaccine produced a stronger immune response than a currently available shot in a late-stage trial, clearing a path forward for the product and ...
Moderna’s mRNA flu shot outperforms existing vaccines in Phase 3 trial, showing over 26% greater efficacy—paving the way for ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results